CellaVision AB (CEVI)
Stockholm Exchange · Sweden · prices in SEK · close of 23 Oct 2026
Key indicators
| Last close | SEK 169.80 |
|---|---|
| 52-week range | 117.60 – 192.20 |
| Return, 1 month / 3 months | +1.1% / +22.2% |
| Return, 1 year / 3 years | −7.4% / +36.6% |
| Trend | Uptrend |
| RSI (14) | 56 |
| Volatility (1 year) | 42.6% |
| Worst drawdown (1 year) | -36.2% |
| Average daily value traded | 4.28M SEK |
| Dividend yield | 1.6% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
CellaVision is a Swedish medical technology company based in Lund that develops automated digital microscopy systems for analysing blood cells. Its instruments and software help hospital and clinical laboratories examine blood smears, with the CellaVision analyzers capturing images of cells and using image analysis to assist laboratory staff in identifying and classifying them. The company serves haematology laboratories and healthcare providers, offering systems together with related software and support services.
CellaVision AB trades under the code CEVI on the Stockholm Exchange in Sweden, with its price quoted in Swedish kronor (SEK). Our dividend records, which start in 2019, show payments in 7 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
CellaVision AB (CEVI) trades on the Stockholm Exchange in Sweden. It last closed at SEK 169.80 on 23 October 2026.
Its price-based Market X-Ray is 69 out of 100 (a fair price profile), ranking 198 of 912 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 7.4% and over the last three months it rose 22.2%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Stockholm Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 85 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 15.4% | ||
| From 52-week high | -9.9% | ||
| Momentum | 72 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 22.2% | ||
| 6-month return | 13.3% | ||
| 12-month return, skipping the last month | -8.4% | ||
| Stability (higher is calmer) | 59 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 42.6% | ||
| Worst drawdown, 1 year (smaller is calmer) | -36.2% | ||
| Liquidity | 73 · Strong | Trades actively. | |
| Average daily value traded | 4.28M SEK | ||
| Zero-volume days | 0.0% | ||
| Income | 42 · Weak | Dividend is small or irregular. | |
| Dividend yield | 1.6% | ||
| Years with dividends | 5 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
- Liquidity: Trades actively.
Weak spots
- Income: Dividend is small or irregular.
Returns
| 1 week | +0.8% |
|---|---|
| 1 month | +1.1% |
| 3 months | +22.2% |
| 6 months | +13.3% |
| 1 year | −7.4% |
| 3 years | +36.6% |
| 5 years | −59.5% |
Signals
| 50-day / 200-day average | 165.02 / 147.13 |
|---|---|
| Golden / death cross (60 days) | Golden, 44 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 4.71 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 29 Apr 2026 | SEK 2.7500 |
| 7 May 2025 | SEK 2.5000 |
| 6 May 2024 | SEK 2.2500 |
| 8 May 2023 | SEK 2.2500 |
| 12 May 2022 | SEK 2.0000 |
| 30 Apr 2021 | SEK 0.7500 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Stockholm Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.